Process of purifying coagulation factor VIII
    2.
    发明授权
    Process of purifying coagulation factor VIII 有权
    凝血因子VIII纯化方法

    公开(公告)号:US08329871B2

    公开(公告)日:2012-12-11

    申请号:US12737230

    申请日:2009-06-24

    IPC分类号: C07K1/16 C07K1/20 C07K1/18

    摘要: A process of purifying or enriching coagulation FVIII employing chromatography comprising the steps of providing a fraction containing FVIII in an aqueous solution having a high ionic strength; contacting the fraction containing FVIII with a multimodal resin; optionally washing the multimodal resin having FVIII adsorbed with an aqueous washing buffer; eluting FVIII containing fractions by an aqueous elution buffer comprising at least one amino acid which is positively charged at pH 6 to 8; and optionally collecting FVIII containing fractions in purified or enriched form.

    摘要翻译: 一种使用色谱法纯化或富集凝血剂FVIII的方法,包括以下步骤:在具有高离子强度的水溶液中提供含有FVIII的级分; 使含有FVIII的级分与多峰树脂接触; 任选地用具有水洗涤缓冲液的FVIII的多峰树脂进行洗涤; 通过含有至少一种在pH6至8下带正电荷的氨基酸的水洗脱缓冲液洗脱含有FVIII的级分; 并任选地以纯化或富集的形式收集含有FVIII的级分。

    Filtration
    4.
    发明申请
    Filtration 审中-公开
    过滤

    公开(公告)号:US20050203285A1

    公开(公告)日:2005-09-15

    申请号:US11064770

    申请日:2005-02-23

    申请人: Stefan Winge

    发明人: Stefan Winge

    摘要: Filtration methods comprise virus-filtering a solution containing a least one macromolecule. The total salt content of the solution for virus-filtering is within the range of from about 0.2 M up to saturation with the salt. Salts that can be used in the filtering methods include sodium chloride, potassium chloride, sodium acetate, sodium citrate, sodium phosphate, potassium dyhydrophosphate and combinations thereof.

    摘要翻译: 过滤方法包括病毒过滤含有至少一种大分子的溶液。 用于病毒过滤的溶液的总盐含量在约0.2M至饱和盐的范围内。 可用于过滤方法的盐包括氯化钠,氯化钾,乙酸钠,柠檬酸钠,磷酸钠,二氢磷酸氢钾及其组合。

    Process for purifying apolipoprotein A or apolipoprotein E
    5.
    发明授权
    Process for purifying apolipoprotein A or apolipoprotein E 失效
    纯化载脂蛋白A或载脂蛋白E的方法

    公开(公告)号:US06423830B1

    公开(公告)日:2002-07-23

    申请号:US09617898

    申请日:2000-07-17

    IPC分类号: A61K3514

    CPC分类号: C07K14/775 C07K14/755

    摘要: The present invention relates to a process for purifying apolipoprotein A (ApoA) or apolipoprotein E (ApoE) from human plasma, by obtaining a fraction of human plasma containing said ApoA or ApoE, prepurifying said fraction in at least one step, binding said ApoA or ApoE to an anion-exchange chromatography gel, and thereafter eluting said ApoA or ApoE from said anion-exchange chromatography gel. The thus produced ApoA or ApoE can be used for the manufacture of a medicament in the treatment of atherosclerosis and cardiovascular diseases, or peripheral atherosclerosis and sepsis as well as in a method for treatment of atherosclerosis and cardiovascular diseases, or peripheral atherosclerosis and sepsis when administered in a therapeutically effective amount.

    摘要翻译: 本发明涉及通过获得含有所述ApoA或ApoE的人血浆级分来纯化来自人血浆的载脂蛋白A(ApoA)或载脂蛋白E(ApoE)的方法,在至少一个步骤中将所述级分预先完成,结合所述ApoA或 ApoE转移到阴离子交换色谱凝胶上,然后从所述阴离子交换色谱凝胶中洗脱所述ApoA或ApoE。 由此产生的ApoA或ApoE可用于制备治疗动脉粥样硬化和心血管疾病或外周动脉粥样硬化和败血症的药物,以及用于治疗动脉粥样硬化和心血管疾病或外周动脉粥样硬化和败血症的方法 治疗有效量。

    PROCESS FOR PURIFYING VITAMIN K DEPENDENT PROTEINS SUCH AS COAGULATION FACTOR IX
    6.
    发明申请
    PROCESS FOR PURIFYING VITAMIN K DEPENDENT PROTEINS SUCH AS COAGULATION FACTOR IX 审中-公开
    维生素K依赖性蛋白质如凝血因子IX的方法

    公开(公告)号:US20130079498A1

    公开(公告)日:2013-03-28

    申请号:US13638234

    申请日:2011-03-30

    IPC分类号: C07K1/22

    摘要: A process of manufacturing a prion-free Vitamin K dependent Protein in a purification sequence employing chromatography characterized in that at least one chromatography step is performed using a multimodal resin providing a fraction containing Vitamin K dependent Protein in an aqueous solution; contacting the fraction containing the Vitamin K dependent Protein with a multimodal resin at a pH between 6-9; optionally washing the multimodal resin having the Vitamin K dependent Protein adsorbed with an aqueous washing buffer to wash away contaminants and retain the Vitamin K dependent Protein, before the Vitamin K dependent Protein is eluted; the Vitamin K dependent Protein is eluting from the multimodal resin at a pH between 6 to 9 in a buffer comprising arginine; and optionally collecting Vitamin K dependent Protein containing fractions in purified or enriched form.

    摘要翻译: 在使用色谱法的纯化序列中制备无朊病毒的维生素K依赖性蛋白质的方法,其特征在于使用在水溶液中提供含有维生素K依赖性蛋白质的级分的多峰树脂进行至少一个层析步骤; 将含有维生素K依赖性蛋白质的级分与6-10之间的pH值的多峰树脂接触; 在维生素K依赖性蛋白质被洗脱之前,任选地洗涤具有维生素K依赖性蛋白质的多峰树脂,其吸附有水性洗涤缓冲液以洗去污染物并保留维生素K依赖性蛋白质; 维生素K依赖性蛋白质在含有精氨酸的缓冲液中从6至9的pH在多峰树脂中洗脱; 并任选地以纯化或富集形式收集含维生素K依赖性蛋白质的级分。

    Method for purification of proteins
    7.
    发明授权
    Method for purification of proteins 有权
    蛋白质纯化方法

    公开(公告)号:US06518406B1

    公开(公告)日:2003-02-11

    申请号:US09598883

    申请日:2000-06-21

    申请人: Stefan Winge

    发明人: Stefan Winge

    IPC分类号: C07K114

    CPC分类号: C07K14/8128 A61K38/00

    摘要: The present invention relates to methods for purification of antithrombin-III (AT-III) by precipitation of impurities. The said methods comprise (a) adding, to a solution comprising antithrombin-III, a saccharide and citrate, in an amount sufficient for impurities to precipitate while antithrombin-III essentially remains in solution; (b) allowing impurities to precipitate; and (c) removing the precipitated impurities, thereby obtaining a solution comprising purified antithrombin-III. The invention also relates to pharmaceutical compositions, obtainable by the said methods, comprising purified antithrombin-III, as well as to reconstituted pharmaceutical compositions essentially free from visible particles.

    摘要翻译: 本发明涉及通过沉淀杂质来纯化抗凝血酶III(AT-III)的方法。 所述方法包括(a)在抗凝血酶III基本上保留在溶液中时,足以使杂质沉淀的量向包含抗凝血酶III的溶液中加入糖和柠檬酸盐; (b)使杂质沉淀; 和(c)除去沉淀的杂质,从而得到包含纯化的抗凝血酶III的溶液。 本发明还涉及可通过所述方法获得的药物组合物,其包含纯化的抗凝血酶III,以及基本上不含可见颗粒的复原药物组合物。

    Purification of antithrombin-III-&agr; and &bgr;
    8.
    发明授权
    Purification of antithrombin-III-&agr; and &bgr; 有权
    抗凝血酶III-α和β的纯化

    公开(公告)号:US06451978B2

    公开(公告)日:2002-09-17

    申请号:US09766887

    申请日:2001-01-19

    申请人: Stefan Winge

    发明人: Stefan Winge

    IPC分类号: C07K1481

    CPC分类号: C07K14/8128 C07K14/47

    摘要: PROTEIN PURIFICATION I The invention relates to processes for preparation of substantially pure antithrombin-III (AT-III), the antithrombin isoforms AT-III&agr; and AT-III&bgr;; and/or histidine-rich glycoprotein (HRGP). The processes comprise separating the said proteins on a cation exchange gel wherein the cation exchanger group is attached to the gel matrix via a linear polymer chain.

    摘要翻译: 蛋白质纯化本发明涉及制备基本上纯的抗凝血酶III(AT-III),抗凝血酶异构体AT-IIIal和AT-IIIbeta的方法; 和/或富含组氨酸的糖蛋白(HRGP)。 所述方法包括在阳离子交换凝胶上分离所述蛋白质,其中阳离子交换剂基团通过线性聚合物链连接到凝胶基质上。

    Purification of plasma proteins
    9.
    发明授权
    Purification of plasma proteins 失效
    血浆蛋白的纯化

    公开(公告)号:US5817765A

    公开(公告)日:1998-10-06

    申请号:US537872

    申请日:1995-10-30

    摘要: Virus inactivating chemicals and/or detergents in an aqueous composition containing a water-soluble plasma protein are reduced by selecting a suitable combination of temperature and concentration above 0.5M of salt with a high salting out effect according to the Hofmeister series, thereby forming vesicles containing the virus inactivating chemical and/or detergent. These vesicles are removed from the aqueous phase, e.g. by phase separation or filtration, and the protein thereafter isolated from the aqueous phase. The water-soluble plasma protein can be e.g. antithrombin III, transferrin or albumin. When the aqueous phase comprises e.g. a salt of citrate or sulphate in a concentration above 1M at room temperature, the reduction of virus inactivating chemical or detergent can be as high as 2000 times or more, giving a final concentration below 5 ppm.

    摘要翻译: PCT No.PCT / SE94 / 00422 Sec。 371 1995年10月30日第 102(e)日期1995年10月30日PCT 1994年5月6日PCT PCT。 公开号WO94 / 26287 日期1994年11月24日根据Hofmeister系列,通过选择温度和浓度高于0.5M盐的盐,具有高盐析效果的合适的组合,减少含有水溶性血浆蛋白质的水性组合物中的病毒灭活化学物质和/或去污剂 从而形成含有病毒灭活化学和/或洗涤剂的囊泡。 这些囊泡从水相中除去,例如, 通过相分离或过滤,然后从水相中分离蛋白质。 水溶性血浆蛋白可以是例如, 抗凝血酶III,转铁蛋白或白蛋白。 当水相包含例如 在室温下浓度高于1M的柠檬酸盐或硫酸盐,病毒灭活化学或洗涤剂的还原可高达2000倍以上,最终浓度低于5ppm。

    Process for Reduction and/or Removal of FXI and FXIa from Solutions Containing said Coagulation Factors
    10.
    发明申请
    Process for Reduction and/or Removal of FXI and FXIa from Solutions Containing said Coagulation Factors 审中-公开
    从含有凝血因子的溶液中减少和/或去除FXI和FXIa的过程

    公开(公告)号:US20140051839A1

    公开(公告)日:2014-02-20

    申请号:US13885612

    申请日:2011-11-16

    IPC分类号: C07K16/00

    CPC分类号: C07K16/00 C07K14/745

    摘要: A process for reduction and/or removal of FXI and FXIa from a source solution containing said coagulation factors and as main components immunoglobulins comprising the following steps: a) contacting the FXI and/or FXIa containing solution with an affinity chromatographic gel wherein heparin or heparan is linked to the matrix material; b) allowing adsorption of FXI and/or FXIa and c) separation of the liquid deprived of FXI and/or FXIa from the adsorption media.

    摘要翻译: 一种从含有所述凝血因子和作为主要组分的免疫球蛋白的源溶液中还原和/或除去FXI和FXIa的方法,包括以下步骤:a)使含FXI和/或FXIa的溶液与亲和层析凝胶接触,其中肝素或肝素 与基质材料相连; b)允许吸附FXI和/或FXIa,以及c)从吸附介质中分离除去FXI和/或FXIa的液体。